Table 2.
Characteristic | Frequency | |||||
---|---|---|---|---|---|---|
Study Design | Randomized controlled trial Observational prospective cohort study Observational retrospective cohort study |
3 7 3 |
||||
Recruitment | Monocentric hospital-based Multicentral hospital-based Population-based |
9 1 3 |
||||
Comparison: intervention vs. general populationa | RP | EBRT | ADT | WW | AS | |
X | 2 | |||||
Xb | 5 | |||||
X | 1 | |||||
X | 1 | |||||
X | 1 | |||||
Comparison: intervention vs. interventiona | RP | EBRT | ADT | WW | AS | |
X | X | X | 1 | |||
X | Xd | 1 | ||||
X | X | 1 | ||||
X vs. Xc | 1 | |||||
Xc | X | 1 | ||||
X | X | 1 | ||||
X | X | 1 | ||||
X | X | X | X | 1 | ||
X | Xe | X | 1 | |||
X | Xf | 1 | ||||
Sample sizes (total population) | <100 101 – 200 780 1463 (after 5 years since randomization) respectively 1413 participants (6 years since randomization) |
6 5 1 1 |
||||
Years since diagnosis/ randomization |
Long-term survivors (5-10 years after diagnosis) Very long-term survivors (10 + years after diagnosis) |
10 3 |
||||
Stage at diagnosis | Localized (T1/T2) PC Locally advanced (T3/T4 any N1/M1) PC Localized & locally advanced PC No information |
3 2 7 1 |
||||
Recurrent PC survivors | No information Excluded Included |
10 1g 2 |
||||
Progressive PC survivors | No information Excluded Included |
5 3 5 |
aSome studies had multiple comparisons
b“Plus ADT and/or clinical progression”
cPlus ADT
dBrachytherapy
eEBRT-C — Conventional radiation; EBRT-HD — High-dose mixed-beam radiation; EBRT-LD — Low-dose mixed-beam radiation; EBRT-MB — Standard protocol/mixed-beam radiation; EBRT-PB — Proton beam radiation
fBrachytherapy
gExcluded because they died